Clinical trials: Asthma Patients
Asthma
Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma
The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on high doses of ICS-LABA.
- Trial name
- NCT01928771
- Testing
- Benralizumab
- Where
- 275 sites in United States, Australia and 15 more
- Volunteers
- 2,681 people
- Sponsor
- AstraZeneca
Asthma
A Study for Observing Severe Asthma in Patients Treated With Tezepelumab
A study involving primary data collection within real-world settings of participants who initiate treatment with tezepelumab for severe uncontrolled asthma.
- Trial name
- NCT05677139
- Testing
- None (Observational Study)
- Where
- 58 sites in Austria, Belgium and 7 more
- Volunteers
- 513 people
- Sponsor
- AstraZeneca
Asthma
A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic Participants
This study is a randomized, double-blind, placebo-controlled multiple dose ascending study in healthy participants and patients with asthma. Healthy participants will be enrolled in Part A and patients with asthma in Part B: 1.
- Trial name
- NCT06947408
- Testing
- IBI3002
- Where
- China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Asthma
Safety and Efficacy of Two Dosages of Inhaled TPI ASM8 Compared to Placebo in Mild to Moderate Asthmatic Patients
This study will evaluate the efficacy, safety and tolerability of two dosages of a new drug TPI ASM8 administered by inhalation for 14 days to mild to moderate asthmatic patients, aged between 18-65, non-smokers .
- Trial name
- NCT00402948
- Testing
- TPI ASM8, ASM8
- Where
- 10 sites in Canada
- Volunteers
- 10 people
- Sponsor
- Syntara
Asthma
A Methodology Study To Look At Genes In Lung Cells And Tissue From Asthmatic Patients
The primary goal of this study is to identify a gene or panel of genes which are differentially expressed in lung cells and tissue from asthmatic patients following administration of Ipratropium bromide and eiTher nebulised…
- Trial name
- NCT00331292
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma
The purpose of this study is to determine the effect of omalizumab, compared to placebo, on clinically significant asthma exacerbation rates in adolescents and adults with asthma.
- Trial name
- NCT00046748
- Testing
- Omalizumab
- Volunteers
- 484 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study Of RV-39 In Patients Who Also Have Asthma
This study will last up to 9 weeks. Subjects will visit the clinic up to 14 times. Certain clinic visits will include a physical examination, lung function tests, inflammatory cell analysis from nasal secretions and/or sputum…
- Trial name
- NCT00503009
- Testing
- fluticasone propionate/salmeterol, fluticasone propionate
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Asthma
Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium
The purpose of this trial was to demonstrate that the efficacy of two treatment arms of the fixed-dose combination product QVM149 was non-inferior to the efficacy of the free combination arm of salmeterol/ fluticasone+ tiotropium…
- Trial name
- ARGON (NCT03158311)
- Testing
- QVM149, Salmeterol/fluticasone plus tiotropium
- Where
- 163 sites in Argentina, Chile and 18 more
- Volunteers
- 1,426 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Subjects, Asthmatic Patients
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-4597 Inhalation in Healthy Subjects and Asthmatic Patients
The primary objective of this randomized, double-blind, single/multiple ascending dose, placebo-controlled Phase I clinical trial was to evaluate the safety and tolerability of SHR-4597 in healthy subjects and asthmatic patients.
- Trial name
- NCT06385964
- Testing
- SHR-4597
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Asthma, Airway Obstruction
Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199
The purpose of this study is to investigate the pharmacodynamics of single doses of AZD3199 in asthmatic patients.
- Trial name
- NCT00736489
- Testing
- AZD3199, Formoterol
- Where
- 4 sites in Denmark, Sweden
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Asthma
The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)
The purpose of this study is to confirm the dose of roflumilast to be used for asthma management by comparing the effects of 250 mcg and 500 mcg oral roflumilast with placebo on pulmonary function and asthma symptoms.
- Trial name
- NCT00076076
- Testing
- Roflumilast
- Where
- 41 sites in United States, Russia and 1 more
- Volunteers
- 822 people
- Sponsor
- AstraZeneca
Asthma
Efficacy (Bronchoprotection) and Safety of Orally Inhaled BI 1744 CL in Patients With Intermittent Asthma
The primary objective of this study is to assess the efficacy (bronchoprotection) and safety of single doses of BI 1744 CL inhalation solution (2, 5, 10 and 20 mcg) delivered via the Respimat® inhaler, in patients with…
- Trial name
- NCT00928668
- Testing
- Olodaterol (BI1744CL)
- Where
- 4 sites in Canada
- Volunteers
- 32 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Study to Compare Severe Asthma Patients Who Start Biologics and Who do Not Start (PROSPECT)
Objectives in this study is to compare the change of lung function after 24 months from baseline between the two groups; one is the patient group who decided to start biologics treatment, and another is the patient group who…
- Trial name
- NCT04808518
- Where
- 28 sites in Japan
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Asthma
Study With GW274150 In Patients With Mild Asthma
This is a study investigating whether 14 days of dosing with GW274150 has a beneficial effect on a model of asthma type inflammation called the allergen-induced late asthmatic response.
- Trial name
- NCT00273013
- Testing
- GW274150, Singulair
- Where
- 2 sites in United Kingdom
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Moderate to Severe Asthma
A Phase Ib Study of RC1416 Injection
This is a Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RC1416 injection in patients with moderate to severe asthma.
- Trial name
- NCT06911866
- Testing
- RC1416
- Where
- 16 sites in China
- Volunteers
- 40 people
- Sponsor
- Nanjing RegeneCore Biotech Co., Ltd.
Asthma
A Randomized Trial Assessing Once Daily Administration of Mometasone Furoate DPI in Asthmatics (Study P02177)
This will be an open-label, randomized, parallel-group comparison of mometasone furoate dry powder inhaler (MF-DPI) 400 mcg once daily administered in the morning vs. the evening for 12 weeks in subjects with asthma.
- Trial name
- NCT00835094
- Testing
- Mometasone furoate
- Volunteers
- 216 people
- Sponsor
- Organon and Co
Pulmonary Disease, Chronic Obstructive
Single Doses GSK159797 On Patient Safety And Lung Function In Patients With Mild To Moderate Asthma
This study was designed to test safety aspects and effects on lung function of a new dry powder version of GSK159797 for asthmatic subjects to inhale.
- Trial name
- NCT00354666
- Testing
- GSK159797
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Asthma, Bronchial, Rhinitis, Allergic, Perennial
Study of MK0476 (Montelukast Sodium) and Effects on Asthma and Nasal Symptoms Upon Exposure to Cats (0476-256)
The purpose of this study is to determine the protective effect of an approved medication on asthma and allergic rhinitis (inflammation of the mucous membrane of the nose) upon exposure to cats.
- Trial name
- NCT00092105
- Testing
- MK0476, montelukast sodium
- Volunteers
- 58 people
- Sponsor
- Organon and Co
Asthma
A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands
The medications being used in this study are individually approved by the Food and Drug Administration (FDA). The medication under investigation is a combination of the two medications in one inhaler.
- Trial name
- NCT00657774
- Testing
- FlutiForm 250/10 ug, FlutiForm 100/10 ug, Oral Prednisone 10mg
- Where
- 19 sites in United States
- Volunteers
- 160 people
- Sponsor
- SkyePharma AG
Asthma
Impact of Tiotropium Add-on Therapy in Patients With Asthma
To evaluate the effectiveness of add on therapy with Tiotropium Respimat® compared to increasing the dose of ICS in patients with a diagnosis of Asthma and on ICS/LABA therapy
- Trial name
- NCT03964220
- Testing
- Tiotropium Respimat®, Inhaled Corticosteroid/Long-acting beta-agonist
- Where
- United States
- Volunteers
- 7,857 people
- Sponsor
- Boehringer Ingelheim